Welcome to our dedicated page for GSK plc SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports its share capital and voting rights position as at 30 November 2025. The company had 4,315,433,684 issued Ordinary Shares of 31 ¼ pence each, of which 236,608,577 Ordinary Shares were held in treasury. After excluding the treasury shares, the total number of voting rights in GSK is 4,078,825,107. Shareholders can use this voting-rights figure to determine whether they need to notify GSK and the UK regulator of any changes in their shareholdings under the applicable transparency rules.
GSK plc reports that, on 28 November 2025, it repurchased 250,000 ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,786.00p and 1,809.50p per share, with a volume‑weighted average price of 1,799.00p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,143,733 ordinary shares under this programme. After these latest purchases, GSK holds 236,608,577 shares in treasury and has 4,078,825,107 ordinary shares in issue, giving a total of 4,078,825,107 voting rights. GSK states that treasury shares represent 5.80% of its voting rights, a figure shareholders can use when determining notification obligations under UK disclosure rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 245,000 ordinary shares of 31¼ pence each on 27 November 2025 as part of its existing share buyback programme. The shares were bought at prices between 1,795.50p and 1,812.00p per share, with a volume‑weighted average price of 1,804.14p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back 10,893,733 ordinary shares. After this latest transaction, it holds 236,358,577 shares in treasury and has 4,079,073,350 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.79% of voting rights, a figure investors can use for ownership and disclosure calculations.
GSK plc reports that it bought back 170,733 of its ordinary shares on 26 November 2025 through BNP Paribas SA, at prices between 1,794.50p and 1,819.50p per share, with a volume-weighted average price of 1,807.55p. These shares will be held as treasury shares as part of the company’s existing buyback programme, which has repurchased 10,648,733 shares since 30 September 2025.
After this transaction, GSK holds 236,113,577 shares in treasury and has 4,079,318,350 ordinary shares in issue, which is also the total number of voting rights in the company. GSK confirms that treasury shares now represent 5.79% of the voting rights, a figure shareholders can use when assessing disclosure thresholds under UK transparency rules.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
GSK plc reported a buyback transaction executed via BNP Paribas SA on 12 November 2025, purchasing 167,000 ordinary shares at a volume‑weighted average price of 1,813.49p (range 1,805.50p–1,827.00p). The shares will be held as treasury shares and form part of the company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 8,663,000 shares. Following this transaction, GSK holds 256,127,844 shares in treasury and has 4,059,300,530 shares in issue (excluding treasury). The total number of voting rights is 4,059,300,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc filed a Form 6‑K reporting its UK block listing six‑monthly return for the period from 1 May 2025 to 31 October 2025, detailing movements under three employee share plans.
Under the GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan, securities issued/allotted were 0, with a balance of unallotted securities of 115,518 at period end.
For the GlaxoSmithKline plc Share Save Plan 2012, securities issued/allotted were 134,547, leaving a balance of unallotted securities of 135,768 at period end.
For the GlaxoSmithKline plc Share Save Plan 2022, securities issued/allotted were 47,674, with a balance of unallotted securities of 904,117 at period end.